News

View
Phase 2b clinical trials set for potential AMD treatment
age related macular degeneration

Phase 2b clinical trials set for potential AMD treatment

More than one million Americans aged 40 and over are affected by geographic atrophy (otherwise known as advanced dry age-related macular degeneration), which currently has no available therapy that...
FDA approves Izervay for treatment of geographic atrophy
AMD

FDA approves Izervay for treatment of geographic atrophy

The Food and Drug Administration (FDA) recently announced their approval of Izervay for treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
FDA approves first drug to treat geographic atrophy
age-related macular degeneration

FDA approves first drug to treat geographic atrophy

Geographic atrophy typically affects people over the age of 50 and is one of the main causes of vision loss in the United States.
AI algorithm may be a helpful tool for determining progression of AMD
AMD

AI algorithm may be a helpful tool for determining progression of AMD

Artificial intelligence may be the key in helping doctors determine which patients with intermediate AMD are at a high risk of the disease progressing to geographic atrophy.
What else can I do?
age-related macular degeneration

What else can I do?

Among the many rewards of formulating premium macular degeneration eye vitamins is the daily positive feedback I receive from my own patients. And the vast majority of them have enjoyed stability i...